Your shopping cart is currently empty

DTX-P7 is a peptide drug conjugate (PDC) composed of Docetaxel (DTX) and a heptapeptide (P7), which induces the unfolded protein response and subsequent apoptosis by degrading Hsp90.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | DTX-P7 is a peptide drug conjugate (PDC) composed of Docetaxel (DTX) and a heptapeptide (P7), which induces the unfolded protein response and subsequent apoptosis by degrading Hsp90. |
| In vitro | DTX-P7 suppresses the expression of membrane-bound Hsp90 in a dose- and time-dependent manner, while no changes are observed at the mRNA level. It also enhances the phosphorylation of PERK and eIF2α; however, XBP-1 mRNA splicing is not observed upon exposure in A549 cells. |
| In vivo | DTX-P7 administered to mice with A549 xenograft tumors (15/30 mg/kg, once weekly for 4 weeks) inhibits tumor growth in dormant/slow-proliferating A549/CD133+ cells by degrading DYRK1A and subsequently allowing cell cycle reentry. |
| Molecular Weight | 1639.87 |
| Formula | C84H118N8O25 |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.